Aether Bio develops machine learning algorithms and proprietary robotic hardware to engineer enzymes for the production of complex biochemical compounds. This technology enables manufacturers to create novel products at significantly reduced costs by efficiently indexing and searching trillions of enzyme sequences.

Ashvattha Therapeutics develops hydroxyl dendrimer-based nanomedicines that selectively target activated cells in inflamed tissues, addressing unmet medical needs in ophthalmology, neurology, and inflammatory diseases. This precision approach enhances treatment efficacy by ensuring that therapeutics are delivered specifically to areas of inflammation, minimizing off-target effects.

Atomic AI develops next-generation RNA-centric medicines using machine learning and structural biology. Their ATOM-1 foundation model provides highly precise predictions of three-dimensional RNA structure, enabling access to previously unreachable therapeutic targets. The proprietary R&D platform integrates deep learning models with purpose-built wet-lab assays to accelerate drug discovery.

Elemind develops wearable neurotechnology designed to improve sleep performance through real-time brainwave modulation. The device uses AI-enhanced acoustic stimulation to guide the user's brain out of wakeful patterns and into deeper sleep on demand. This drug-free system offers advanced sleep analytics and aims to enhance recovery and cognitive function through optimized sleep cycles.

The startup has developed a neural-network-enabled filmmaking platform that uses artificial intelligence to visually translate foreign language films by adjusting actors' mouth movements. This technology allows businesses to provide dubbed content in multiple languages while preserving the original performance nuances of the actors.

Generate Biomedicines utilizes generative biology and machine learning to design and produce novel therapeutic proteins, including antibodies and enzymes, with high precision and efficiency. The platform addresses the limitations of traditional drug discovery by enabling on-demand generation of medicines tailored to specific therapeutic functions, significantly accelerating the development process.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

The startup develops deterministic single-core streaming architectures that predict performance and compute time for various workloads. This technology enhances computing speed, quality, and energy efficiency in artificial intelligence and quality-performance computing applications.

Harbinger Health develops a two-tier blood testing model that detects early-stage cancer by identifying biological markers present before tumor formation. This approach addresses the limitations of current cancer detection methods, making early screening accessible and affordable for all individuals.

Ignota Labs focuses on rescuing promising but abandoned drug candidates that failed clinical trials due to safety issues. The company utilizes its proprietary AI platform, SAFEPATH, which combines deep learning with bioinformatics and cheminformatics data to understand and mitigate drug toxicity mechanisms. This approach allows Ignota Labs to rapidly advance viable assets through development, offering new therapeutic options to patients faster than de novo discovery.

This biotech company develops a non-viral gene integration platform for precision genome engineering. Their integrase-based technology enables the targeted insertion of large genes into the human genome, offering a safer and more efficient method for manufacturing biologics and vaccines.

Keikku provides an FDA-cleared smart stethoscope that captures and analyzes physical exam sounds like heart and lung sounds. This device integrates with an AI medical scribe that automatically transcribes, structures, and generates SOAP-ready clinical notes. The platform facilitates seamless deployment of structured data, including ICD-10 and CPT codes, directly into major EHR systems.

Lila applies artificial intelligence to enhance the scientific method by automating data analysis and hypothesis testing. This technology addresses inefficiencies in research processes, enabling faster and more accurate scientific discoveries.

March Biosciences develops CAR‑T cell therapies for hard‑to‑treat hematologic cancers, focusing on target unlocking without additional gene editing. The company emphasizes high cell quality and a streamlined manufacturing process to produce consistent, robust CAR‑T products. Its lead candidate, MB‑105, targets CD5 for relapsed/refractory T‑cell lymphoma.

Ozlo Sleep develops specialized audio technology in the form of Sleepbuds, designed to enhance sleep quality by masking disruptive noises and promoting relaxation. These earbuds address the challenge of sleep disturbances without medication, providing users with a non-invasive solution to improve their sleep rituals.

Provides a cloud-based digital pathology platform that enables pathologists to upload, manage, and share whole slide images across clinical, educational, and research settings. By integrating HL7-compatible LIS systems and AI-powered image analysis tools, it streamlines workflows, improves diagnostic accuracy, and facilitates global collaboration among healthcare institutions.

Perceptive designs and manufactures a handheld intraoral scanner utilizing optical coherence tomography (OCT) technology to capture 3D volumetric data with over 90% accuracy for caries detection, eliminating the need for ionizing radiation. The company is also developing a dental robotics system aimed at completing restorative procedures in 15 minutes, significantly reducing the time and complexity of traditional methods.

Rubedo Life Sciences is a clinical-stage biotech company focused on developing therapeutics that target the pathologic cells driving aging. The company utilizes its Alembic discovery platform to identify novel drug candidates aimed at promoting biological youthfulness. Their pipeline includes GPX4 modulators designed to address chronic diseases associated with the aging process.

The startup provides accessible and affordable diagnostic services for sexual wellness, respiratory health, and chronic conditions through a user-friendly telehealth platform. This technology enables consumers to obtain timely health assessments and lab tests, addressing the barriers of cost and accessibility in healthcare.

Starling Medical develops UrinDx™, a home-based urine monitoring device that provides real-time health insights to detect urinary tract infections (UTIs) early. This technology enables proactive health management and connects users with clinical care, reducing the risk of recurrent UTIs and hospitalizations.

Tiny Health offers microbiome testing for families, utilizing stool and vaginal swab samples analyzed in a CLIA-certified lab to identify gut imbalances. The platform provides personalized action plans to address chronic conditions such as eczema and allergies, promoting optimal gut health from infancy through adulthood.

Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.